TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04356716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Initial Sildenafil dosage will be weight dependent. Participants will start at 40 mg daily (20mg in the morning, 20 mg in the evening) or 60 mg daily (40mg in the morning and 20 mg in the evening). Sildenafil dosage may be increased to up to 80mg daily (20-40mg in the morning and 20-40mg in the evening) based on the response to lower doses. If the participant has not had improvement after initial treatment, the dose may be increased, at the discretion of the study physician.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Sildenafil
Description: Medical record review of participants that receive Sildenafil as part of standard of care.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ocular Coherence Tomography-Angiography (OCT-A)
Description: Retinal photographs will be taken at each study visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual Acuity (VA)
Description: Visual acuity will be measured with Snellen Eye Chart at each study visit.
Study: NCT01999725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-788
Description: EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules or matching suspension
Study: NCT03668093

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICCM
Description: comprehensive system for caries management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAMBRA
Description: Caries risk assessment model
Study: NCT01488201

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Study: NCT00038558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim SD/01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Study: NCT00820716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
Study: NCT00815893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine 1.0 mcg/kg infusion for 10minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: 0.9% Normal Saline 0.25ml/kg infusion for 10minues
Study: NCT00952146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transgastric peritoneoscopy (NOTES)
Description: Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
Study: NCT00815893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol 1%
Description: Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion.
Study: NCT02038075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy (BCBT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Study: NCT03565614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reablement
Description: Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional home care
Description: Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
Study: NCT04186871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: abatacept
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: branebrutinib placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: branebrutinib placebo
Description: Specified dose on specified days
Study: NCT04558021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niclosamide suspension
Description: 200mg/10ml
Study: NCT04186871

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: branebrutinib placebo
Description: Specified dose on specified days
Study: NCT00713895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert System
Description: an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Self-Help
Description: standard smoking cessation self-help manual
Study: NCT03145948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-553
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-553
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-553
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-553
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-553
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-553
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: It is administered orally.
Study: NCT02071069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: 180 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
Study: NCT02969460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurotrack Virtual Cognitive Health Program
Study: NCT03970291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMD-200
Description: The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
Study: NCT02557828

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arterial line placement
Description: radial arterial cannulation placed via palpation or ultrasound technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arterial line placement
Description: radial arterial cannulation placed via palpation or ultrasound technique
Study: NCT03083613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: Raltitrexed:3mg/m2,iv,d1, Every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
Study: NCT03765554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 Immediate release tablets
Description: Small molecule tablets in immediate release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 Immediate release tablets
Description: Small molecule tablets in immediate release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 Modified release tablets
Description: Small molecule tablets in modified release form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841 Modified release tablets
Description: Small molecule tablets in modified release form
Study: NCT02486380

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee full face mask/toffee nasal mask
Description: Toffee full face mask/toffee nasal mask
Study: NCT02122536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects
Description: Subjects were randomized to which side of the face would be treated with Xeomin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects
Description: Subjects were randomized to which side of the upper face would be treated with Botox
Study: NCT01212718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FUFA
Description: 2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy
Description: CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
Study: NCT01941472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluid challenge
Description: A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
Study: NCT04390620

Intervention type: DEVICE
Intervention: Mucosal Closure
Description: mucosal closure in oral surgery (mucosal sutures)
Study: NCT01619176

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: methotrexate: 7.5mg/week to 15mg/week for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-steroidal anti-inflammatory drug (NSAID)
Description: NSAID: 100mg twice a day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: leflunomide: 20mg/day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: methotrexate: 7.5mg/week to 15mg/week for 3 months
Study: NCT01167231

Intervention type: DRUG
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
Study: NCT03792672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.
Study: NCT01619176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-steroidal anti-inflammatory drug (NSAID)
Description: NSAID: 100mg twice a day for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leflunomide
Description: leflunomide: 20mg/day for 3 months
Study: NCT01996085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indapamide/hydrochlorothiazide
Description: 1. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm)~2. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: Drug choice at the discretion of physician (blinded to ICG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Drug choice at the discretion of physician (blinded to ICG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indapamide/hydrochlorothiazide
Description: Drug choice at the discretion of physician (blinded to ICG)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Drug choice at the discretion of physician (blinded to ICG)
Study: NCT00810992

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional and behavioral program A
Description: Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional and behavioral program B
Description: Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
Study: NCT04558021

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10ml placebo(absent of niclosamide)
Study: NCT01439399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine,
Description: Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
Study: NCT03997110

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course palliative radiation.
Description: Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long course palliative treatment.
Description: Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
Study: NCT03802591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1001 monoclonal antibody
Description: Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CS1001 placebo
Description: Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered by oral, twice a day on Day 1 - Day 14 of each cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Administered by oral, twice a day on Day 1 - Day 14 of each cycle.
Study: NCT02597387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone HCL Liposome Injection
Study: NCT03361982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow Freezing and Thawing
Description: half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
Study: NCT03025243

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: computer aided surgical guide
Description: comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computer aided surgical guide
Description: comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
Study: NCT01619176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20.
Study: NCT00519597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResMed S8 (Auto-CPAP)
Description: AutoCPAP during sleep

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed S8 (Auto-CPAP)
Description: AutoCPAP during sleep
Study: NCT02406131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
Study: NCT04320901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure
Description: Ligasure™ Maryland Jaw Laparoscopic Sealer/Divider 37cm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harmonic
Description: Harmonic ACE 7+
Study: NCT01418742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab, Doxycycline/Placebo
Description: comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Panitumumab
Description: mCRC patients receiving panitumumab as EGFR inhibitor.
Study: NCT01291407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
Study: NCT03792672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-653
Description: TAK-653 tablets.
Study: NCT00544674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: administered at a dose of 1100 mg/m\^2 by intravenous infusion over 1 hour and repeated every three weeks